Clinical Aspects of Psychopharmacology in Childhood and Adolescence. Second Edition

Donald E. Greydanus, M.D. (Editor)
Department of Pediatric and Adolescent Medicine, Western Michigan University School of Medicine, Kalamazoo, MI, USA

Joseph L. Calles, Jr., Ph.D. (Editor)
Department of Psychiatry, Western Michigan University
Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA

Dilip R. Patel, M.D. (Editor)
Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA

Ahsan Nazeer (Editor)
Dept. of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA

Joav Merrick, M.D., MMedSci, DMSc, (Editor)
Division of Adolescent Medicine, KY Children’s Hospital, Department of Pediatrics, Lexington, Kentucky, USA
National Institute of Child Health and Human Development, Jerusalem, Israel
Division of Pediatrics, Hadassah Hebrew University Medical Centers, Mt Scopus Campus, Jerusalem, Israel
School of Public Health, Georgia State University, Atlanta, Georgia, USA

Series: Pediatrics, Child and Adolescent Health
BISAC: MED105020

Clear

$230.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

The search for medicinal agents to improve emotional, behavioral, and psychiatric conditions of Homo sapiens has occurred for ages. The 20th century witnessed the development of psychopharmacologic agents, including stimulants in the 1930s (and 1950s), chlorpromazine in the 1950s, lithium, tricyclic antidepressants, benzodiazepines, SSRIs (1990s), and others. The proper use of these agents in the pediatric population continues to be an active study. Atypical antipsychotics have been approved by the FDA for children and adolescents though their safety and efficacy in the pediatric population but must be assiduously ascertained with ongoing research in the eternal iatric maxim of primum non nocere.

The science of evidence-based pharmacotherapy for mental health disorders in children and adolescents is finally emerging. Exciting discoveries await the researchers of this still early 21st century lead by the crucial collaborative efforts of academicians, pharmaceutical scientists, and medical government authorities. Controversies regarding the use of various psychopharmacologic agents for the pediatric population continue in the 21st century, requiring further research and insightful judgment for its applications in this vulnerable population. Excessive and unnecessary psychopharmacologic agents should be avoided in the pediatric population with behavioral/emotional/psychiatric conditions/disorders. In this second edition, the authors present updated information about psychopharmacology in childhood and adolescence. (Imprint: Nova Biomedical)

Dedication

Foreword

Introduction

Chapter 1. Pediatric Psychopharmacology: Perspectives of History
Donald E. Greydanus and Joav Merrick (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America, and others)

Section One: Attention Deficit Hyperactivity Disorder

Chapter 2. Attention Deficit Hyperactivity Disorder: Pharmacologic Management in Children and Adolescents
Gabriel Kaplan, Jeffrey H. Newcorn and Iliyan S. Ivanov (Department of Psychiatry, Bergen Regional Medical Center, Paramus, New Jersey, United States of America, and others)

Chapter 3. Attention Deficit Hyperactivity Disorder and Comorbid Substance Abuse
Iliyan Ivanov, Andrew Pearson, Gabriel Kaplan, and Jeffrey Newcorn (Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States of America, and others)

Section Two: Mental Health Aspects

Chapter 4. Psychotherapy in the Age of Pharmacology
Helen D. Pratt (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 5. Depression: Major Depressive and Dysthymic Disorders
Joseph L. Calles, Jr. and Ahsan Nazeer (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 6. Pediatric Bipolar Disorder
Ahsan Nazeer and Joseph L. Calles, Jr. (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 7. Anxiety Disorders in Children and Adolescents
Dilip R. Patel, Kelly A. Brown and Donald E. Greydanus (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 8. Oppositional Defiant and Conduct Disorders
Joseph L. Calles, Jr. and Ahsan Nazeer (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 9. Control of Aggression and Violence
Joseph L. Calles, Jr. and Ahsan Nazeer (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicne, Kalamazoo, Michigan, United States of America)

Chapter 10. Tic Disorders in Children and Adolescents: Principles of Psychopharmacologic Management
Donald E. Greydanus (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Section Three: Specific Disorders

Chapter 11. Autism Spectrum Disorders
Ahsan Nazeer and Joseph L. Calles, Jr. (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 12. Schizophrenia in Children and Adolescents
Ahsan Nazeer and Joseph L. Calles, Jr. (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 13. Cognitive-Adaptive Disabilities
Joseph L. Calles, Jr. and Ahsan Nazeer (Department of Psychiatry, Western Michigan University Homer Stryker MD School of Medicne, Kalamazoo, Michigan, United States of America)

Section Four: Other Use

Chapter 14. Sleep Disorders in Children and Adolescents
Donald E. Greydanus (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 15. Pharmacological Agents for Smoking Cessation
Dilip R. Patel and Donald E. Greydanus (Department of Pediatrics and Adolescent Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, United States of America)

Chapter 16. Substance use Disorders in Adolescents: Pharmacologic Management
Donald E. Greydanus (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America)

Section Five: Conclusion

Chapter 17. Pediatric Psychopharmacology: Quo Vadis, Where do We go From Here?
Donald E. Greydanus and Joav Merrick (Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America, and others)

Section Six: Acknowledgements

Chapter 18. About the Editors

Chapter 19. About the Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine (WMED), Kalamazoo, Michigan United States

Chapter 20. About the National Institute of Child Health and Human Development in Israel

Chapter 21. About the Book Series “Pediatrics, Child and Adolescent Health”

Section Seven: Index

Index

You have not viewed any product yet.